I have already written a lot about experimental immunotherapies. Previous posts have ranged from the strong signs of clinical activity already seen by anti-PD1 checkpoint therapies in MSI-high Colorectal Cancer (CRC), to an overview of why the more common non-MSI CRC has been… Read More
↧